PLX — Protalix Biotherapeutics Inc
NYSE MKT · Healthcare · Biotechnology
$2.63
+$0.04 (+1.54%)
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on NYSE MKT. It is led by Dror Bashan, based in 2 University Plaza, Hackensack, NJ, United States, 07601, with about 213 employees. Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Latest reported PLX revenue for 2025-09-30 was $17.9M. Net income was -$1.1M. Revenue was up 14.0% from 2025-06-30 to 2025-09-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Use this PLX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PLX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PLX SEC filings page. Lician reads the product cache first so this HTML stays unique to Protalix Biotherapeutics Inc even when a live quote feed is slow.
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
PLX Key Statistics
Market Cap
$122.59M
Volume
497,742
Previous Close
$2.41
Day Range
$2.38 – $2.43
P/E Ratio
30.80
EPS
$0.04
Revenue
$53.40M
Net Income
$2.93M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-18.5%
Profit Margin
5.5%
Employees
213
PLX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $53.40M | $65.49M | $47.64M | $38.35M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $2.93M | $8.31M | -$14.93M | -$27.58M |
| EPS (Diluted) | $0.04 | $0.09 | -$0.31 | -$0.62 |
Total Assets
$73.42M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.76M
Operating Cash Flow
$8.67M
Free Cash Flow
$0.00
Protalix Biotherapeutics Inc Company Information
- President, CEO & Director
- Dror Bashan
- Headquarters
- 2 University Plaza, Hackensack, NJ, United States, 07601
- Website
- www.protalix.com
- Phone
- 201 696 9345
- IPO / Founded
- 1998-05-15
- Sector
- Healthcare
- Industry
- Biotechnology